Corporate Banner
Satellite Banner
Technology Networks Header
Tuesday, July 29, 2014
Technology Networks
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
Researchers Uncover New Cancer Cell Vulnerability
The research showed that telomerase-expressing cells depend upon a gene named p21 for their survival.
Capturing Cancer: A Powerful New Technique for Early Diagnosis
Researchers describe an innovative technique for early disease detection, which they call immunosignaturing.
No Extra Mutations in Modified Stem Cells, Study Finds
New results ease previous concerns that gene-editing techniques-used to develop therapies for genetic diseases-could add unwanted mutations to stem cells.
Patient-Specific Stem Cells and Personalized Gene Therapy
Patients’ own cells transformed into model for studying disease and developing potential treatment.
Significant Step Towards Blood Test for Alzheimer's
Scientists have identified a set of 10 proteins in the blood which can predict the onset of Alzheimer’s, marking a significant step towards developing a blood test for the disease.
Novel Insights into the Control of Gene Expression
The webinar, “Developing new insights into gene expression using RNA-Seq”, sees Dr Christopher Jones, Research Fellow at the Brighton and Sussex Medical School present novel findings from a recent RNA-Seq project performed by OGT.
Aging Contributes to Rapid Rates of Genomic Change
Signaling challenges for personalized medicine.
CRI Finds Key to Identifying, Enriching Mesenchymal Stem Cells
Biomarker enables researchers to accurately characterize the properties and function of MSCs in the body.
Saturated Fat Intake May Influence Person’s Expression of Genetic Obesity Risk
Limiting saturated fat could help people whose genetic make-up increases their chance of being obese.
Genetic Material Hitchhiking in Our Cells May Shape Physical Traits
Explaining the connection between genotype and phenotype must also consider genetic material that doesn’t come from an organism’s chromosomes at all.
Scroll Up
Scroll Down
Return
Multi Center Validation of a New Molecular Diagnostic Assay for Accurate and Rapid Screening of JAK2 V617F Mutation
Fabienne Hermitte, CSO, Ipsogen, speaking at the Molecular Diagnostics World Congress 2007
Date Posted: Monday, May 19, 2008
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



IPSOGEN Expands its U.S. Presence through Licensing Agreement with Quest Diagnostics
Ipsogen entered a non-exclusive license agreement with Quest for the use of the JAK2 V617F mutation in Quest Diagnostic's laboratory developed tests.
Tuesday, October 07, 2008
IPSOGEN Expands its U.S. Presence Through Licensing Agreement with Quest Diagnostics
Ipsogen SA, a molecular diagnostic company specialized in the development, manufacturing and commercialization of diagnostic assays for breast cancer and leukemia, today announced a non-exclusive license agreement with Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, for the use of the JAK2 V617F mutation in Quest Diagnostic's laboratory developed tests.
Monday, October 06, 2008
Ipsogen Launches MapQuant Dx™ Genomic Grade Test to Analyze Chemotherapy Results
The Company expects that by improving the accuracy of tumor grading, the test could spare tens of thousands chemotherapy treatments per year.
Monday, June 02, 2008
Ipsogen Announces Three Studies at the American Society of Clinical Oncology Meeting
The results from the studies extend the utility of the Genomic Grade index for predicting response to chemotherapy in breast cancer.
Monday, May 26, 2008
IPSOGEN Licenses the Genomic Grade™ to Improve Breast Cancer Diagnosis & Treatment Decision
IPSOGEN signed a license agreement with Universite Libre de Bruxelles (ULB), Belgium for the worldwide and exclusive rights on the Genomic Grade™.
Monday, January 28, 2008
Ipsogen Reports Recommendation of JAK2V617F Mutation Screening in WHO 2008 Criteria and Point-of-Care Diagnostic Algorithms
The 2008 revision of the WHO document on the classification of CMPDs has incorporated new information on the molecular pathogenesis of BCR–ABL negative myeloproliferative disorders including the screening for JAK2V617F mutation.
Tuesday, January 22, 2008
IPSOGEN Grants Labcorp License for Leukemia Molecular Diagnostic Assay in USA
IPSOGEN grants LabCorp non-exclusive rights to offer an assay for the diagnosis of a group of leukemias caused by JAK2 gene variations.
Tuesday, September 11, 2007
Ipsogen Grants Exclusive License to Warnex to Market a Leukemia Molecular Diagnostic Service in Canada
Ipsogen grants Warnex exclusive rights to market a service for the diagnosis and the classification of a group of leukemias.
Thursday, August 16, 2007
Ipsogen Presents Breast Cancer Biomarker Results at the EBCC 5
These results concern the identification on 323 patient samples.
Monday, February 27, 2006
 
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv